AMAG Pharmaceuticals
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, AMAG Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
AMAG Pharmaceuticals: 23 sponsored US clinical trials, 2 recruiting.
AMAG Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 15 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Kidney Disease; Iron Deficiency Anemia, with 1 trials.
Top-decile sponsor footprint
AMAG Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
NCT03893045
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
NCT03619850
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
NCT04593784
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
NCT03973047
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
NCT03008616
Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
NCT02937766
Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
NCT02940522
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
NCT02694978
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
NCT01227616
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
NCT01264679
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
NCT01155388
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
NCT01155375
A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
NCT01146990
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
NCT01114217
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
NCT01114139
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
NCT01052779
Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
NCT01004029
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
NCT00707876
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
NCT00360425
A Crossover Safety Study of Ferumoxytol Versus Placebo
NCT00255450
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
NCT00233597
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
NCT00255437
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
NCT00255424
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
Where AMAG Pharmaceuticals enrollment is open (later-stage tilt)
2 recruiting of 23 indexed (9% open); 15 completed (65%).
Phase mix: 15 late (III/IV) vs 7 early (I/II) (later-stage heavy).
Top condition: Chronic Kidney Disease; Iron Deficiency Anemia (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AMAG Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 23 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
AMAG Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
- Duramed Research · 23 trials · 0% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Iowa State University · 9% recruiting · 23 trials
- New Approaches to Neuroblastoma Therapy Consortium · 9% recruiting · 23 trials
- Rhythm Pharmaceuticals · 9% recruiting · 23 trials
- Swedish Orphan Biovitrum · 9% recruiting · 23 trials
Related
What to do with this AMAG Pharmaceuticals page
23 registered trials is a research-attention snapshot, not an endorsement of AMAG Pharmaceuticals or any single study.
- 2 of AMAG Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Kidney Disease; Iron Deficiency Anemia is the condition AMAG Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Kidney Disease; Iron Deficiency Anemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AMAG Pharmaceuticals pipeline card: 23 registered trials from official public datasets.Report a data error.